GLP-1R Signaling and Functional Molecules in Incretin Therapy
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). The GLP-1R cellular signaling mechanism relevant to insulin secretion and blood glucose regulation has been extensively studied. Numerous drugs targeting GLP-1R have entered clinical treatment. However, novel functional molecules with reduced side effects and enhanced therapeutic efficacy are still in high demand. In this review, we summarize the basis of GLP-1R cellular signaling, and how it is involved in the treatment of T2DM. We review the functional molecules of incretin therapy in various stages of clinical trials. We also outline the current strategies and emerging techniques that are furthering the development of novel therapeutic drugs for T2DM and other metabolic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Signaling pathways of GLP-1R in pancreatic β-cell [15,30]. Three downstream signaling pathways initiated from Gαs (blue), Gαq (pink), and β-arrestin (green) are shown in the left half of the β-cell. The GLP-1R internalization process and insulin secretion after GLP-1R activation are also shown. Colored circles show mono-agonists targeting GLP-1R (red), GIPR (green), and GCGR (blue), and multi-agonists targeting GLP-1R/GIPR (red/green), GLP-1R/GCGR (red/blue), and GLP-1R/GIPR/GCGR (red/green/blue). The top left inset shows the structure of GLP-1R with a seven-transmembrane helix bundle and a large ECD. Abbreviations: VDCC, voltage-dependent calcium channel; TRPM, the transient receptor potential melastatin; GCGR, glucagon receptor; GIPR, gastric inhibitory polypeptide receptor.](https://figures.cochat.ai/paper-figures/acbea23bdcdd42f9b5434df4875a1968/glp-1r-signaling-and-functional-molecules-in-incretin-therapy-figure-1.jpg)
![Figure 2 Development strategies for GLP-1R ligands [16,52,53]. (A) Amino acid sequences of GLP-1 (7-36) amide, exendin-4, and oxyntomodulin. Different residues from GLP-1 are in bold type. DPP-4 deactivates the GLP-1 (7-36) amide by cleaving it after the second amino acid (alanine) from the N-terminal and leads to the short circulation time of GLP-1 (7-36) in human body. (B) Several chemical modifications and their combinations can be applied in GLP-1R peptide agonist development, including C-terminal amidation, acylation, PEGylation, and substitution. (C) GLP-1R peptide ligands can fuse to Fc region of antibody, antibody, and albumin. (D) Three typical small-molecule agonists for GLP-1R: LY-3502970 and PF-06882961 are under clinical trials, while TT-OAD2 has failed.](https://figures.cochat.ai/paper-figures/974caae933284bd1bbb4d72559d12870/glp-1r-signaling-and-functional-molecules-in-incretin-therapy-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with GLP-1RAs can alleviate insulin signaling by reducing the phosphorylation of Akt protein (Decreased Akt-P) and activating Protein Kinase C-ε (PKC-ε).485,486”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [485]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9 · cited 1×
“A recent study reported that PX17, an updated agent based on P5, shows greater blood glucose modulation and body weight reduction compared with semaglutide [146].”
BackgroundRetracted10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 2×
“Two types of β-arrestin, β-arrestin-1 and β-arrestin-2, mediate the GLP-1R downstream signaling in β-cells, and also elicit the receptor internalization process. β-arrestin-1 mediates the phosphorylation of CREB and ERK1/2 [42], further phosphorylating Bad (Bcl-xL/Bcl-2-associated death promoter homolog) and inhibitin…”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 1×
“Lixisenatide Adlyxin SC, qd T2DM 2016 [74] Beinaglutide Yishengtai SC, tid T2DM 2016 [75] [76] [77] Semaglutide Ozempic Rybelsus Wegovy SC, qw PO 2, qd SC, qw T2DM T2DM Obesity 2017 2019 2021 [78] PEG-Loxenatide Fulaimei SC, qw T2DM 2019 [79] PEGylated Exenatide (PB-119) / SC, qw T2DM Phase 3 [80] Efpeglenatide (SAR43…”
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 6×
“PF06882961 stays in the orthosteric binding pocket in the TMD, almost overlapping with the binding sites of the N-terminal of GLP-1 [28].”
BackgroundInfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“Tirzepatide Mounjaro / SC, qw T2DM Obesity 2022 2022 FTD 2 [90,91] [86] CT-868 / SC, qd T2DM Phase 1 / NNC0090-2746 (RG7697) / SC, qd T2DM Phase 2 [92] GLP-1R/GLP-2R Dapiglutide (ZP7570) / SC, qw SBS Phase 1 / GLP-1R/GCGR”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431 · cited 2×
“yethylene glycol (PEG) units to the peptide [58], while fatty acid acylation allows the co-”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Liraglutide Victoza Saxenda SC, qd T2DM Obesity 2010 2014 [68,69] [70] Dulaglutide Trulicity SC, qw T2DM 2014 [71]”
Background2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Research works printed but not linked: 1
- Buckeridge, 2022, Once-daily oral small molecule GLP-1R agonist PF-07081532 robustly reduces glucose and body weight within 4-6 weeks in adults with type 2 diabetes and non-diabetic adults with obesity, Diabetologia, 65, S60
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“485,486 This affects the synthesis of triacylglycerol (TAG), phosphatidic acid (di-P PA), and diacylglycerol (DAG) in the liver.”
BackgroundRhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Emerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 53
“This canonical pathway promotes insulin granule exocytosis while simultaneously suppressing inappropriate glucagon secretion from α -cells [51,52].”
Cryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins
Cong, Z., Zhao, F., Li, Y., Luo, G., Mai, Y., Chen, X., Chen, Y., Lin, S., Cai, X., Zhou, Q., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00649-0 · Cited by 31
Binding sites and design strategies for small molecule GLP-1R agonists
Zhang, H., Wu, T., Wu, Y., Peng, Y., Wei, X. H., Lu, T., & Jiao, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116632 · Cited by 29
Self-citationDelrue, C., & Speeckaert, M. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179351 · Cited by 28
“These agonists offer numerous benefits, including increased β -cell activity, cardioprotection, and anti-inflammatory and neuroprotective characteristics [7,19].”
BackgroundInfluentialThe foot in diabetes – a reminder of an ever-present risk
Craus, S., Mula, A., & Coppini, D. (2023) · Clinical Medicine · doi:10.7861/clinmed2022-0489 · Cited by 26
“89 Lifestyle interventions including feasible exercise in addition to patient education may play a role in the management of persons with DFD, 90–92 but it remains unknown what the exact effect is and which educational approach is most effective.”
BackgroundWawrzak-Pienkowska, K., Pienkowski, T., Golonko, A., Krupa, A., Warpechowski, M., Płoński, A. F., Mojsak, P., Daniluk, J., Dâbrowski, A., & Kurek, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178290 · Cited by 12
Impaired brain glucose metabolism in glucagon-like peptide-1 receptor knockout mice
Li, H., Fang, Y., Wang, D., Shi, B., & Thompson, G. J. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00343-w · Cited by 13
“We found that (1) GLP-1R KO mice exhibit impaired brain glucose metabolism to high doses of exogenous glucose; (2) GLP-1R KO mice have reduced functional connectivity when measured across the whole brain.”
BackgroundGLP-1R in diabetes mellitus: from basic discovery to therapeutics development
Li, S., Huang, N., Wang, M., Huang, W., Luo, Y., & Huang, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1610512 · Cited by 21
Stapled peptides as potential therapeutics for diabetes and other metabolic diseases
Nielipinska, D., Rubiak, D., Pietrzyk‐Brzezinska, A. J., Małolepsza, J., Błażewska, K. M., & Gendaszewska‐Darmach, E. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117496 · Cited by 10
Dong, G., Ye, Q., Li, W., Zhang, S., Yang, Z., Zhang, R., Ta, D., Li, H., Zhang, Y., Zhang, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00242 · Cited by 10
Effects of liraglutide on ANP secretion and cardiac dynamics
Luo, S., Zuo, Y., Cui, X., Zhang, M., Jin, H., & Hong, L. (2023) · Endocrine Connections · doi:10.1530/ec-23-0176 · Cited by 8
“GLP-1R is a class of G protein-coupled receptors that can be activated by polypeptide agonists and is an effective therapeutic target for a variety of diseases (28, 29, 30, 31).”
Alavi, S. E., Boshrouyeh, R., Raza, A., & Shahmabadi, H. E. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118587 · Cited by 6
Analysis of the management and therapeutic performance of diabetes mellitus employing special target
Sun, H., & Lin, X.-Y. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i12.1721 · Cited by 10
Kour, S., & Singh, S. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100825 · Cited by 9
Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP‐1, GIP, and Glucagon Agonists
Khan, M. S., Bhutani, U., Venugopal, H., Saini, A. K., Naidu, V. R., & Kollipara, S. (2026) · Journal of Peptide Science · doi:10.1002/psc.70083 · Cited by 7
“Similarly, PEGylation (attachment of polyethylene glycol [PEG] chains) is another strategy used to increase the stability and half-life of peptide drugs by protecting them from enzymatic degradation [34].”
Supramolecular oral delivery technologies for polypeptide-based drugs
Chen, J., Liu, T., Wang, M., Lü, B., Bai, D., Shang, J., Chen, Y., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.045 · Cited by 5
Insights into the structure and activation mechanism of some class B1 GPCR family members
Aksu, H., Demirbilek, A., & Uba, A. İ. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09876-w · Cited by 6
“Glucagon-like peptide receptor types 1 and 2 (GLP1R and GLP2R) respond to glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), respectively [14, 15].”
Liu, C., Bao, X., Tian, Y., Xue, P., Wang, Y., & Li, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0295451 · Cited by 5
“GLP-1R, a member of the class B1 family of G protein-coupled receptors, plays a crucial role in hormone signal reception and receptor activation through its 7-transmembrane protein structure and N-terminal extracellular domain [9].”
BackgroundChronotropic Responses to GLP-1 Receptor Agonists and Sitagliptin in Atria From Diabetic Rats
Akcabag, E., Aksoyalp, Z. Ş., Öner, F., Bayram, Z., Özbey, G., Nacıtarhan, C., Özdem, S., Taşatargil, A., & Özdem, S. S. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001564 · Cited by 3
“20 26 Thus, we also investigated nitric oxide (NO), potassium channels, reactive oxygen species, and cyclooxygenase products as possible mechanisms involved in the effects of GLP-1 analogs and sitagliptin on HR in the isolated rat atrium.”
BackgroundA New Protractor Potentiates Glucagon-Like Peptide 1 with Slow-Release Depot and Long-Term Action
Jing, W., Peng, L., Song, S., Liu, J., & Tai, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02970 · Cited by 3
Regulation of Human Sortilin Alternative Splicing by Glucagon-like Peptide-1 (GLP1) in Adipocytes
Lui, A., Patel, R. S., Krause‐Hauch, M., Sparks, R. P., & Patel, N. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814324 · Cited by 3
“GLP1 mediates its effects via a G-protein-coupled receptor and signals through the PI3K/AKT, PKA/cAMP, and PKC pathways [73,74].”
BackgroundConroy, L., McCann, A., Zhang, N., & de Gaetano, M. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00695.2023 · Cited by 5
Li, W. (2024) · Preprints.org · doi:10.20944/preprints202402.1519.v1 · Cited by 3
Mirghani, H. O., Albishi, L. A., & Alblewi, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758755 · Cited by 2
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
Pu, W., Pan, Y., Yang, K., Gao, J., Tian, F., Song, J., Huang, Y., & Li, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1575450 · Cited by 1
“GLP-1R provides signi fi cant protection to pancreatic function, when activated by GLP-1, releases cAMP as a second messenger to activate downstream signaling pathways, thereby exerting antidiabetic effects (Wan et al., 2023).”
Lin, M.-P., Xue, B.-J., & Bai, X. (2026) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-026-10759-7 · Cited by 2
“Specifically, IP 3 interacts with its receptor, resulting in the Ca 2+ influx [10].”
Curto, R., Giglione, C., Cannarella, R., Berisha, H., Hattab, R., Condorelli, R. A., Vignera, S. L., Calogero, A. E., & Magni, P. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108278 · Cited by 2
Xiao, Y., Wang, R., Long, Y., Dai, W., & Nie, H. (2025) · ChemistrySelect · doi:10.1002/slct.202501324
Characterizing the role of extracellular domain in GLP-1R biased agonism
Xie, L., Xu, R., Liu, H., Na, M., Qin, Q., Xu, F., Stevens, R. C., & Liu, Y. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106867
Self-citationHu, J., Zhou, Y., Liu, S., Li, J., Tian, L., & Liang, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00044-5
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Saldívar-Cerón, H. I. (2026) · Scientia Pharmaceutica · doi:10.3390/scipharm94010021
“Fc-fusion and peptide–antibody conjugates, exemplified by maridebart cafraglutide, prolong half-life by engaging neonatal Fc receptor (FcRn) recycling and reducing renal clearance, enabling sustained GLP-1 receptor activation with infrequent injections [14,20,36–38].”
Thirumurthy, M. A., de león, J. S. A. D., Pan, S., & Ly, N. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00091
Moreno, K., Gualán, J., Toapanta, J., & Barahona, A. S. C. (2026) · Innova Science Journal · doi:10.63618/omd/isj/v4/n2/252 · Cited by 5
Kurowski, M., Rekiel, K., Marcinkowska, A., Ratajczyk, O., Urbanowicz, P., Iwankiewicz, S., Grzelczak, W., & mierczak, Z. K. (2026) · Medical Journal of Cell Biology · doi:10.2478/acb-2026-0005
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
Badrealam, K. F., Alameri, R. M., Raouf, Y. S., Maurel, D., Wani, N. A., Shmygol, A., Anwar, I., See, H. B., Johnstone, E. K. M., Dupuis, E., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70677
GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Koceva, E., & Moll, G. N. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179406
BindingDB Entry 50022117: Binding sites and design strategies for small molecule GLP-1R agonists.
BindingDB (2025) · UC San Diego · doi:10.7270/q2474gk6
Metadata
- Authors
- Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y.
- Affiliations
- ShanghaiTech University (CN)
- Structure Therapeutics, South San Francisco, CA 94080, USA
- Corresponding author
- Stevens, Raymond C.
- Liu, Yan
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2023-01-11
- Volume
- 28
- Issue
- 2
- Pages
- 751
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC9866634
- OpenAlex
- W4315781708
- Cited by
- 44
- References
- 168
- Citations by year
- 2026: 13 · 2025: 13 · 2024: 12 · 2023: 6
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- ShanghaiTech University (21ZR1442500)
- Shanghai Municipal Government (21ZR1442500)
- Shanghai Frontiers Science Center for Biomacromolecules and Precision Medicine at ShanghaiTech University (21ZR1442500)
- Science and Technology Commission of Shanghai Municipality (21ZR1442500)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- GLP-1 receptor, incretin-based therapy, type 2 diabetes, insulin secretion, blood glucose regulation, GLP-1 receptor agonists, GLP-1 receptor antagonists, drug development, metabolic disorders
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Insulin, Signal Transduction, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.